A MULTICENTRIC STUDY ON BREAST CANCER IN ULTRA YOUNG WOMEN: III – THERAPEUTIC ASPECTS AND ONCOLOGICAL OUTCOMES

Adriana Akemi Yoshimura¹, André Mattar², Bruna S. Mota³, Carlos Elias Fristachi⁴, Eduardo Carvalho Pessoa⁵, Felipe Eduardo Andrade⁶, Giuliano Tosello⁷, Heloísa Maria De Luca Vespoli⁸, Idam de Oliveira Junior⁹, João Bosco Ramos Borges⁹, José Roberto Filassi¹⁰, Luiz Henrique Gebrim¹, Marina Filie Haddad Piccinilli¹⁰, René Aloisio Costa Vieira⁸, Vicente Tarriconi Junior¹⁰, Alfredo Carlos Simões Dornellas de Barros¹

¹Hospital da Beneficência Portuguesa – São Paulo (SP), Brazil.
²Hospital Pérola Byington – São Paulo (SP), Brazil.
³Instituto do Câncer do Estado de São Paulo – São Paulo (SP), Brazil.
⁴Instituto Arnaldo Vieira de Carvalho – São Paulo (SP), Brazil.
⁵Hospital das Clínicas de Botucatu – Botucatu (SP), Brazil.
⁶Hospital Sírio Libanês – São Paulo (SP), Brazil.
⁷Hospital Regional de Presidente Prudente – Presidente Prudente (SP), Brazil.
⁸Hospital do Amor – Barretos (SP), Brazil.
⁹Faculdade de Medicina de Jundiaí – Jundiaí (SP), Brazil.
¹⁰Faculdade de Ciências Médicas de Santos – Santos (SP), Brazil.

Introduction: We have originally introduced the concept of ultra young women (UYW), defined as age ≤30 years old. It is generally accepted that UYW patients with breast cancer (BC) share some unfavorable outcomes and the patients are faced with family and professional problems, and unique quality of life issues, including loss of fertility, contraception, pregnancy, sexuality, cancer during pregnancy, body image and emotional distress, that complicate treatment decisions making. Objectives: Study the type of surgical and systemic treatment and oncologic outcomes in UYW with BC. Methods: We conducted a multicentric, observational, retrospective study of consecutive BC UYW patients. Only patients with infiltrating BC were included. Nine Mastology Centers located in the State of São Paulo participated. The following data were recorded: type of surgery, chemotherapy, endocrinotherapy, and radiotherapy. Individual oncologic evolution was analyzed and the patients were classified as alive without disease (AWD), alive with local recurrence (ALR), alive with systemic recurrence (ASR), died from BC (DBC) or died from another cause (DOC). The research protocol was approved by the Ethics Committee of all Collaborative Centers. Results: Sixteen percent of UYW with BC underwent mastectomies, 10% nipple-sparing mastectomies and 16% breast conservative surgeries. About 50% had immediate breast reconstruction. Sentinel node biopsy was performed in 24%. 18% had more than four compromised LNs, 8% with extracapsular leak. 37% received adjuvant or palliative chemotherapy. 61% were submitted to irradiation. 54% had adjuvant hormonotherapy. The mean time of follow-up was 41.5 months (1.5-207). It was observed that 59% were AWD, 1% ALR, 7% ASR and 23% DBC, unfortunately standing out the elevated contingent of BC-related deaths. Conclusions: BC therapy in UYW were tailored according to individual characteristics, but the oncological outcomes in this age range at the moment could be considered unfavorable.